

State of Oklahoma





SoonerCare

Member Name:	Date of Birth:	Member ID#:		
	Drug Information			
Pharmacy Billing (NDC: Dose:	Regimen:	date of next dose):		
	Pharmacy Information			
-	-	ne:		
Pharmacy Phone: Pharmacy Fax: Prescriber Information				
Prescriber NPI:	Prescriber Name:			
Prescriber Phone:	Prescriber Fax:			
	Criteria			
For Initial Authorization (Initial approval will be for the duration of 6 months): 1. Please indicate the diagnosis and information: Chronic Myeloid Leukemia (CML) A. Chronic, accelerated, or blast phase CML? Yes No B. Newly diagnosed or resistant/intolerant to other Tyrosine Kinase Inhibitors TKIs)? Yes No Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) A. Used as upfront therapy (including induction and consolidation) in combination with multi-agent chemotherapy or a single agent? Yes No B. Used as maintenance therapy including any of the following? Yes No As a single agent and unfit for additional therapies As a single agent and previously received blinatumomab plus a tyrosine kinase inhibor (TKI) In combination with vincristine and prednisone, with or without methotrexate and mercaptopurine Post-hematopoietic stem cell transplant C. Used as a single agent or in combination with multi-agent chemotherapy for relapsed/refractory disease? Yes No Does member have any of the following mutations of BCR-ABL1: T315I, V299L, G250E, F317L? Yes No Additional Information:				
(Page 1 of 2)				
(Page 1 of 2)				

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma.

This document, including any attachments, contains information which is
confidential or privileged. If you are not the intended recipient, be aware
that any disclosure, copying, distribution, or use of the contents of this
information is prohibited. If you have received this document in error,
please notify the sender immediately by telephone to arrange for the retui
of the transmitted documents or to verify their destruction.



State of Oklahoma



SoonerCare

Bosulif[®] (bosutinib) Prior Authorization Form

Ме	mber Name: Date of Birth: Member ID#:
	Criteria
Fo	r Continued Authorization:
1.	Date of last dose:
2.	Does member have any evidence of progressive disease while on bosutinib? Yes No
3.	Has the member experienced any adverse drug reactions related to bosutinib therapy? Yes No
	If yes, please specify adverse reactions:
Ac	ditional Information:

(Page 2 of 2)

Prescriber Signature:

Date:

I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge. Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma. CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.